NICE confirms ‘no’ for colorectal cancer drugs
pharmafile | November 24, 2011 | News story | Sales and Marketing | Erbitux, NICE, Vectibix, avastin, colorectal cancer
NICE has issued final draft guidance not recommending Merck Serono’s Erbitux (cetuximab), Roche’s Avastin (bevacizumab) and Amgen’s Vectibix (panitumumab), for the treatment of metastatic colorectal cancer that has progressed after first line chemotherapy. |
|
Andrew Dillon, chief executive of NICE said: “We have already recommended six treatments for various stages of colorectal cancer and are disappointed not to be able to add these three drugs, cetuximab, bevacizumab and panitumumab to the list of treatments for this stage of the disease. “However, we have to be confident that the benefits that drugs offer patients really do justify what the NHS will have to pay for them. The independent appraisal committee which drafted the recommendations does not feel it has enough evidence, especially in the case of bevacizumab, to feel confident in recommending these drugs for use on the NHS.” NICE first rejected Erbitux and Avastin for colorectal cancer in January 2007, and the watchdog’s new review says the drugs are still not sufficiently cost-effective. Advertisement
None of the treatments met the criteria to be considered under NICE’s special arrangements for drugs to help people facing the end of their lives. The draft guidance is now with consultees, who have the opportunity to appeal against it. Until NICE issues final guidance, NHS bodies should make decisions locally on the funding of specific treatments. None of these treatments have been approved for second line use of metastatic colorectal cancer in Scotland. Patients in England now have a means of overcoming NICE’s no on cancer drugs, however. The Cancer Drugs Fund (CDF), first set up in October 2010, allows cancer patients in England to receive drugs either not yet appraised by NICE or already rejected. Figures show that Avastin is one of the drugs most frequently funded through the regional committees, which are allocated a share of the £600 million annual fund. Between October 2010 and March 2011, a total of 1,040 funding requests for Avastin were approved in England through the CDF. |
Andrew McConaghie
Related Content
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Ryvu Therapeutics publishes research revealing potential drug combination for colorectal cancer
Ryvu Therapeutics has published new findings from its ONCO Prime target discovery platform in Scientific …
Neogap receives approval to administer full dose in cell therapy trial for colorectal cancer
Neogap Therapeutics has received regulatory approval from the Swedish Medical Products Agency to administer the …
